We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Phynova | LSE:PYN | London | Ordinary Share | GB00B0YBCM49 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.375 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMPYN Phynova Group PLC 28 July 2009 28 July 2009 Phynova Group PLC ("Phynova" or the "Company") Phynova Announces Collaboration with Chrysalis Health & Beauty Solutions Limited ("Chrysalis") to Promote and Commercialise Candidate Functional Ingredient and Over the Counter ("OTC") Products in Europe Phynova (AIM: PYN), the developer of prescription pharmaceuticals, functional ingredients for the cosmetic, food and supplement industries and OTC products capable of being registered under the Traditional Herbal Medicinal Products scheme, today announces that it has signed a Collaborative Framework Agreement with Chrysalis. Chrysalis is a specialist company based in Nottingham providing consultation services and products to the Health and Beauty sectors. Under the agreement Phynova will use Chrysalis' services over the next two years for the promotion and commercialisation of Phynova's functional ingredient and OTC product candidates in Europe. Phynova's product candidates include 'BCL-6', a skin anti-ageing ingredient, and other functional food ingredients with potential in the treatment of Type II diabetes and in combating fatigue and improving sleep quality in middle aged and older people. Phynova is collaborating in the development of these products with its joint venture partner in China, Botanic Century Beijing Ltd ("BCCL") and has a collaboration with Tasly Modern Chinese Medicine Resource Ltd, a subsidiary of the Tasly Group of Tianjin, China, one of the world's largest producers of botanical drugs. Phynova is also developing products suitable for registration under the EU's Traditional Herbal Medicinal Products (THMP) scheme and is already in discussion with a number of companies seeking to create new brands or to maintain OTC herbal products on the market in compliance with the EU Directive's 2011 deadline for registration. Phynova's CEO Robert Miller commented "As we have reported previously Phynova is developing several pipeline opportunities capable of generating near term revenues in the functional ingredient and OTC markets. With this agreement we believe we have added greatly to our chances of achieving commercial success. The team at Chrysalis supplies us strong complementary capabilities, with support in areas such as formulation and pricing, proof of efficacy testing, ingredient and product promotion and brand development. We believe Chrysalis will help shorten the time to achieving commercial success on the path that begins with our own discoveries and those of our collaborators in China." For further information, please contact: +-------------------------------------+-------------------------------------+ | Phynova Group PLC | | +-------------------------------------+-------------------------------------+ | Robert Miller (CEO) | +44 (0) 1993 880700 | +-------------------------------------+-------------------------------------+ | Tony Mills (CCO) | | +-------------------------------------+-------------------------------------+ | | | +-------------------------------------+-------------------------------------+ | Nominated Adviser and Broker: | | +-------------------------------------+-------------------------------------+ | John East & Partners Limited, a subsidiary of Merchant Securities PLC | +---------------------------------------------------------------------------+ | John East/Simon Clements | +44 (0) 20 7628 2200 | +-------------------------------------+-------------------------------------+ Notes to Editors: About Phynova Phynova is a UK company developing new prescription pharmaceuticals derived from plants used in Chinese medicines, functional ingredients for the cosmetic, food and supplement industries and OTC products capable of being registered under the Traditional Herbal Medicinal Products scheme. For further information please visit www.phynova.com. About Chrysalis Health & Beauty Chrysalis Health & Beauty is a UK company specialising in the commercialisation of new products and concepts for use in the Health & Beauty markets. With extensive in-house technical and marketing experience, Chrysalis works with academic, research-orientated and marketing-based organisations offering clear routes to market and numerous services. Clients vary from businesses requiring advice and assistance in taking a new product to market, to companies wishing to outsource the entire commercial aspects of particular projects. With a worldwide network of partners, Chrysalis can help to launch products on a global scale rapidly and effectively. Chrysalis' typical clients include Brands, R&D companies, Retailers and Manufacturers of raw materials or finished goods. For further information please visit www.chrysalisweb.com. This information is provided by RNS The company news service from the London Stock Exchange END NRARPMPTMMTTMIL
1 Year Phynova Chart |
1 Month Phynova Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions